Enhanced therapeutic response with addition of loratadine in subserosal eosinophilic gastroenteritis.
A case of a 45-year-old Caucasian male initially reported with symptoms of acute intestinal obstruction was presented. Diagnostic tests revealed presence of eosinophilic ascites with marked peripheral eosinophilia, a significant thickening of stomach and intestinal wall and infiltration of gastric and duodenal mucosa with eosinophiles. Findings were conclusive with subserosal type of eosinophilic gastroenteritis and the patient's treatment started with a combination of parenteral methylprednisolone and oral loratadine. A prompt clinical response was encountered after 5 days of treatment with complete resolution.
1Department of Gastroenterology and Hepatology, Clinic of Inter- nal  Medicine; 2Department of Pathology, Division of Laboratory Diagnostics; University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina.
Nermin N
NN
Salkić
Jasminka
J
Mustedanagić-Mujanović
Predrag
P
Jovanović
Ervin
E
Alibegović
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D001201:Ascites / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D004751:Enteritis / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004802:Eosinophilia / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004804:Eosinophils / Q000166:cytology; D005756:Gastritis / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology; D017336:Loratadine / Q000627:therapeutic use*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D015415:Biomarkers; D005938:Glucocorticoids; D017336:Loratadine; D008775:Methylprednisolone